Pharma Mar (OTCMKTS:PHMMF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, January 25th.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Pharma Mar (OTCMKTS:PHMMF) traded down $0.01 during trading hours on Thursday, reaching $2.04. The company had a trading volume of 10,546 shares, compared to its average volume of 23,682. Pharma Mar has a 1 year low of $1.84 and a 1 year high of $4.80.
TRADEMARK VIOLATION WARNING: “Pharma Mar (PHMMF) Stock Rating Lowered by Zacks Investment Research” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/20/zacks-investment-research-lowers-pharma-mar-phmmf-to-sell.html.
Pharma Mar Company Profile
Pharma Mar, SA, a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. It develops and commercializes YONDELIS, a novel, multimodal, synthetically produced antitumor agent for the treatment of advanced soft tissue sarcomas as a single-agent, as well as for relapsed ovarian cancer in combination with Doxil/Caelyx.
Get a free copy of the Zacks research report on Pharma Mar (PHMMF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.